CELLUVISC

This brand name is authorized in Australia, Finland, France, Germany, Hong Kong SAR China, Ireland, Netherlands, South Africa, Tunisia, UK.

Active ingredients

The drug CELLUVISC contains one active pharmaceutical ingredient (API):

1	Carmellose sodium UNII K679OBS311 - CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED
	Carmellose sodium has no pharmacological effect. Carmellose sodium has a high viscosity resulting in an increased retention time on the eye.
	Read more about Carmellose

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CELLUVISC Eye drops, solution	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S01XA20	Artificial tears and other indifferent preparations	S Sensory organs → S01 Ophthalmologicals → S01X Other ophthalmologicals → S01XA Other ophthalmologicals
Discover more medicines within S01XA20

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	2324H, 5505R
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	04145356, 04145379, 04922943, 04922966
FI	Lääkealan turvallisuus- ja kehittämiskeskus	039768
FR	Base de données publique des médicaments	66976254
GB	Medicines & Healthcare Products Regulatory Agency	182980, 283988, 283989, 283991, 283993, 284036, 284037, 284041, 284043, 284045
HK	Department of Health Drug Office	42106
IE	Health Products Regulatory Authority	17007, 17061, 17062, 17070, 17083
NL	Z-Index G-Standaard	14847175
NL	Z-Index G-Standaard, PRK	68950
TN	Direction de la Pharmacie et du Médicament	5473151
ZA	Health Products Regulatory Authority	30/15.4/0144